CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 57.66×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.90BTWD310.10M · vs all stocks (USD)
Revenue (TTM)
0.00TWDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.3570xvs all stocks
52-Week Change
-23.68%vs all stocks
Market Capitalization
9.90BTWD310.10M · vs all stocks (USD)
Enterprise Value
6.72BTWD210.52M · vs all stocks (USD)
Price to Book (MRQ)
3.89xvs Biotechnology peers
Enterprise to EBITDA
-13.41xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-16.33%vs Biotechnology peers
Return on Equity (TTM)
-24.52%vs Biotechnology peers
Revenue (TTM)
0.00TWDvs all stocks (USD)
Revenue per Share (TTM)
0.00TWDUpdated Aug 21, 2026Gross Profit (TTM)
0.00TWDvs all stocks (USD)
EBITDA (TTM)
-500.92MTWD-15.70M · vs all stocks (USD)
Net Income (TTM)
-464.34MTWD-14.55M · vs all stocks (USD)
Operating Cash Flow (TTM)
-365.80MTWD-11.46M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-210.48MTWD-6.60M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00TWDFY2025 · Dec 31, 2025Cost of Goods Sold
0.00TWDFY2025 · Dec 31, 2025Gross Profit
0.00TWDFY2025 · Dec 31, 2025Operating Income
-456.38MTWD-14.30M · vs all stocks (USD)
Pre-tax Income
-444.77MTWDFY2025 · Dec 31, 2025Income Tax Expense
0.00TWDFY2025 · Dec 31, 2025Net Income
-444.77MTWDFY2025 · Dec 31, 2025EBIT
-443.34MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-417.83MTWDFY2025 · Dec 31, 2025Research & Development
369.77MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
86.61MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
19.56MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.42MTWDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-444.77MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-390.89MTWDFY2025 · Dec 31, 2025Free Cash Flow
-415.92MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
970.89MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-444.77MTWDFY2025 · Dec 31, 2025Stock-based Compensation
75.13MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-18.14MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.38MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
271.00KTWDFY2025 · Dec 31, 2025Capital Expenditures
-25.03MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-226.00KTWDFY2025 · Dec 31, 2025Purchase of Investments
-200.00MTWDFY2025 · Dec 31, 2025Sale of Investments
100.00MTWDFY2025 · Dec 31, 2025Other Investing Activity
6.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-125.03MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
15.91MTWDFY2025 · Dec 31, 2025Shares Outstanding
85.57MSharesUpdated Aug 21, 2026Float Shares
50.58MSharesUpdated Aug 21, 2026% Held by Insiders
47.44%vs all stocks
% Held by Institutions
3.97%vs all stocks
Total Cash (MRQ)
2.19BTWD68.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
24.65TWDUpdated Aug 21, 2026Total Debt (MRQ)
53.73MTWD1.68M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0231xvs Biotechnology peers
Current Ratio (MRQ)
57.66xvs Biotechnology peers
Book Value per Share (MRQ)
26.12TWDUpdated Aug 21, 2026Total Assets
1.37BTWD42.79M · vs all stocks (USD)
Total Current Assets
1.22BTWDFY2025 · Dec 31, 2025Total Liabilities
94.22MTWDFY2025 · Dec 31, 2025Total Non-current Assets
143.74MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
53.42MTWDFY2025 · Dec 31, 2025Total Current Liabilities
40.80MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
970.89MTWDFY2025 · Dec 31, 2025Other Short-term Investments
200.00MTWDFY2025 · Dec 31, 2025Short-term Debt
11.65MTWDFY2025 · Dec 31, 2025Other Current Liabilities
288.00KTWDFY2025 · Dec 31, 2025Long-term Debt
47.86MTWDFY2025 · Dec 31, 2025Common Stock (Book)
855.73MTWDFY2025 · Dec 31, 2025Retained Earnings
-444.77MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.27BTWD39.83M · vs all stocks (USD)
52-Week Low
86.10TWDUpdated Aug 21, 202652-Week High
236.00TWDUpdated Aug 21, 202652-Week Change
-23.68%vs all stocks
Beta
-0.3570xvs all stocks
50-Day MA
100.85TWDUpdated Aug 21, 2026200-Day MA
148.59TWDUpdated Aug 21, 2026Avg 10-Day Volume
418.05KSharesUpdated Aug 21, 2026Avg 30-Day Volume
296.94KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-5.40TWDUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 57.66×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 57.66Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OmniAb, Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Chengdu Guoguang Electric Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
BTQ Technologies Corp.
4 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Juneway Electronic Technology Co.
4 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration